Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence

International Journal of Cancer

Volumn 137, Issue 5, 2015, Pages 1158-1166

  Andrew, Angeline S ^a   Marsit, Carmen J ^a   Schned, Alan R ^a   Seigne, John D ^a   Kelsey, Karl T ^b   Moore, Jason H ^a   Perreard, Laurent ^a   Karagas, Margaret R ^a   Sempere, Lorenzo F ^c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

bladder cancer; miR; miRNA; recurrence; urothelial carcinoma

Indexed keywords

MICRORNA 34A; MICRORNA; MIRN34 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; UNITED STATES; BLADDER TUMOR; CELL LINE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; NEW HAMPSHIRE; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; UROTHELIUM;

ADULT; AGED; CELL LINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEW HAMPSHIRE; PROGNOSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84931567498     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29413     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Gonzalgo ML, Jones PA,. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res 1997; 25: 2529-31.
3. Montie J, Shipley W., Bladder cancer including upper tract tumors and transitional cell carcinoma of the prostate National Comprehensive Cancer Network Practice Guidelines in Oncology. Fort Washington, PA: National Comprehensive Cancer Network, 2004.
4. Silverman DT, Morrison AS, Devesa SS., Bladder'cancer. In:, Schottenfeld D, Fraumeni JF,. Cancer epidemiology and prevention, 2nd edn. New York: Oxford University Press, 1996. 1156-79.
5. Kirkali Z, Chan T, Manoharan M, et al., Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34.
6. Jemal A, Siegel R, Xu J, et al., Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
7. Brown LM, Zahm SH, Hoover RN, et al., High bladder cancer mortality in rural new england (united states): an etiologic study. Cancer Causes Control 1995; 6: 361-8.
8. Michaud DS, Clinton SK, Rimm EB, et al., Risk of bladder cancer by geographic region in a U.S. cohort of male health professionals. Epidemiology 2001; 12: 719-26.
9. Burger M, Catto JW, Dalbagni G, et al., Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-41.
10. Burger M, Oosterlinck W, Konety B, et al., ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2013; 63: 36-44.
11. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al., Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 2007; 25: 285-95.
12. Petrovich Z, Baert L, Boyd SD, et al., Management of carcinoma of the bladder. Am J Clin Oncol 1998; 21: 217-22.
13. Honma I, Masumori N, Sato E, et al., Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 2004; 64: 744-8.
14. Botteman MF, Pashos CL, Redaelli A, et al., The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30.
15. Strope SA, Montie JE,. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 2008; 180: 31-7; discussion 7.
16. Schmitz-Drager BJ,. Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications. Eur Urol 2011; 60: 721-3.
17. Mendell JT, Olson EN,. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172-87.
18. Bartel DP,. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
19. Trang P, Weidhaas JB, Slack FJ,. MicroRNAs as potential cancer therapeutics. Oncogene 2008; 27 Suppl 2: S52-7.
20. Ventura A, Jacks T,. MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136: 586-91.
21. Sempere LF, Kauppinen S., Translational implications of MicroRNAs in clinical diagnostics and therapeutics. In:, Bradshaw RA, Dennis EA, eds. Handbook of Cell Signalinged. Oxford: Academic Press, 2009. 2965-81.
22. Nana-Sinkam SP, Croce CM,. Clinical applications for microRNAs in cancer. Clin Pharmacol Therap 2013; 93: 98-104.
23. Catto JW, Miah S, Owen HC, et al., Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 2009; 69: 8472-81.
24. Veerla S, Lindgren D, Kvist A, et al., MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009; 124: 2236-42.
25. Lodygin D, Tarasov V, Epanchintsev A, et al., Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-600.
26. Zhang C, Yao Z, Zhu M, et al., Inhibitory effects of microRNA-34a on cell migration and invasion of invasive urothelial bladder carcinoma by targeting notch1. J Huazhong Univ Sci Technolog Med Sci 2012; 32: 375-82.
27. He L, He X, Lim LP, et al., A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-4.
28. Christoffersen NR, Shalgi R, Frankel LB, et al., p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 2010; 17: 236-45.
29. Lal A, Thomas MP, Altschuler G, et al., Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet 2011; 7: e1002363
30. Zhao J, Lammers P, Torrance CJ, et al., TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther 2013; 21: 1678-86.
31. Dyrskjot L, Ostenfeld MS, Bramsen JB, et al., Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009; 69: 4851-60.
32. Pignot G, Cizeron-Clairac G, Vacher S, et al., Microrna expression profile in a large series of bladder tumors: identification of a 3-mirna signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 2013; 132: 2479-91.
33. Marsit CJ, Houseman EA, Christensen BC, et al., Identification of methylated genes associated with aggressive bladder cancer. PLoS One 2010; 5: e12334.
34. Schned AR, Andrew AS, Marsit CJ, et al., Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the northeastern United States. Scand J Urol Nephrol 2008; 42: 237-42.
35. Sempere LF, Preis M, Yezefski T, et al., Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010; 16: 4246-55.
36. Sens DA, Park S, Gurel V, et al., Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol Sci 2004; 79: 56-63.
37. Sempere LF., Fully automated fluorescence-based 4-color multiplex assay for co-detection of microRNA and protein biomarkers in clinical tissue specimens. Methods Mol Med 2014; 1211: 151-170.
38. Neely LA, Rieger-Christ KM, Neto BS, et al., A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 2010; 28: 39-48.
39. Liu X, Sempere LF, Ouyang H, et al., MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010; 120: 1298-309.
40. Chiyomaru T, Enokida H, Tatarano S, et al., miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102: 883-91.
41. Maccani MA, Padbury JF, Marsit CJ,. miR-16 and miR-21 expression in the placenta is associated with fetal growth. PLoS One 2011; 6: e21210
42. Yamamura S, Saini S, Majid S, et al., MicroRNA-34a modulates c-myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One 2012; 7: e29722.
43. Vinall RL, Ripoll AZ, Wang S, et al., Devere white RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-rb pathway status. Int J Cancer 2012; 130: 2526-38.
44. Vogt M, Munding J, Gruner M, et al., Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011; 458: 313-22.
45. Higgins JP, Kaygusuz G, Wang L, et al., Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007; 31: 673-80.
46. Tothova V, Gibadulinova A,. S100P, a peculiar member of S100 family of calcium-binding proteins implicated in cancer. Acta Virol 2013; 57: 238-46.
47. Penumutchu SR, Chou RH, Yu C,. Structural insights into calcium-bound S100P and the V domain of the RAGE complex. PLoS One 2014; 9: e103947.
48. Guo L, Chen S, Jiang H, et al., The expression of S100P increases and promotes cellular proliferation by increasing nuclear translocation of beta-catenin in endometrial cancer. Int J Clin Exp Pathol 2014; 7: 2102-12.
49. Ling H, Fabbri M, Calin GA,. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847-65.
50. Bader AG,. miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 120.
51. Mirna Therapeutics Inc. A phase I study of MRX34 given intravenously in patients with unresectable primary liver cancer or metastatic cancer with liver involvement, www.clinicaltrials.gov/ct2/show/NCT01829971.